Trials / Completed
CompletedNCT00801944
Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
Solifenacin in the Treatment of Urgency Symptoms of Overactive Bladder in a Rising Dose, Randomized, Placebo-controlled, Double-blind Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 973 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Solifenacin succinate | oral |
| DRUG | Placebo | oral |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2008-12-04
- Last updated
- 2014-09-18
Locations
78 sites across 14 countries: Belgium, Czechia, Egypt, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Russia, Slovakia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00801944. Inclusion in this directory is not an endorsement.